Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
RXII's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RXII: No Debt )
RXII' s 10-Year Cash to Debt Range
Min: 0.35   Max: No Debt
Current: No Debt

Equity to Asset 0.52
RXII's Equity to Asset is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RXII: 0.52 )
RXII' s 10-Year Equity to Asset Range
Min: -1.04   Max: 0.52
Current: 0.52

-1.04
0.52
Interest Coverage No Debt
RXII's Interest Coverage is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RXII: No Debt )
RXII' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: -2.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -5493.83
RXII's Operating margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RXII: -5493.83 )
RXII' s 10-Year Operating margin (%) Range
Min: -13376.29   Max: -5250.38
Current: -5493.83

-13376.29
-5250.38
Net-margin (%) -5467.28
RXII's Net-margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RXII: -5467.28 )
RXII' s 10-Year Net-margin (%) Range
Min: -13278.35   Max: -5244.36
Current: -5467.28

-13278.35
-5244.36
ROE (%) -134.97
RXII's ROE (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RXII: -134.97 )
RXII' s 10-Year ROE (%) Range
Min: -423.41   Max: -423.41
Current: -134.97

ROA (%) -70.57
RXII's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RXII: -70.57 )
RXII' s 10-Year ROA (%) Range
Min: -603.25   Max: -140.08
Current: -70.57

-603.25
-140.08
ROC (Joel Greenblatt) (%) -4362.75
RXII's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RXII: -4362.75 )
RXII' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -11835.59   Max: -3597.18
Current: -4362.75

-11835.59
-3597.18
» RXII's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with RXII

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 13.90
RXII's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RXII: 13.90 )
RXII' s 10-Year P/B Range
Min: 4.91   Max: 13.98
Current: 13.9

4.91
13.98
P/S 174.10
RXII's P/S is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RXII: 174.10 )
RXII' s 10-Year P/S Range
Min: 42.2   Max: 357
Current: 174.1

42.2
357
EV-to-EBIT -3.10
RXII's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RXII: -3.10 )
RXII' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -3.1

Current Ratio 11.71
RXII's Current Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RXII: 11.71 )
RXII' s 10-Year Current Ratio Range
Min: 0.48   Max: 11.98
Current: 11.71

0.48
11.98
Quick Ratio 11.71
RXII's Quick Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RXII: 11.71 )
RXII' s 10-Year Quick Ratio Range
Min: 0.48   Max: 11.98
Current: 11.71

0.48
11.98

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.14
RXII's Price/Net Cash is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RXII: 5.14 )
RXII' s 10-Year Price/Net Cash Range
Min: 6.14   Max: 11.92
Current: 5.14

6.14
11.92
Price/Net Current Asset Value 19.64
RXII's Price/Net Current Asset Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RXII: 19.64 )
RXII' s 10-Year Price/Net Current Asset Value Range
Min: 8.75   Max: 47.44
Current: 19.64

8.75
47.44
Price/Tangible Book 13.50
RXII's Price/Tangible Book is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. RXII: 13.50 )
RXII' s 10-Year Price/Tangible Book Range
Min: 8.14   Max: 35.58
Current: 13.5

8.14
35.58

Business Description

Industry: »
Compare: » details
Traded in other countries:44R.Germany
RXi Pharmaceuticals Corp was incorporated in Delaware as a wholly owned subsidiary of Galena on September 8, 2011 in preparation for its planned spin-off from Galena, which was completed on April 27, 2012. The Company is a biotechnology company. Its main business activities are discovering, developing and commercializing therapies based on its proprietary, new-generation RNA interference platform. Its proprietary therapeutic platform is comprised of novel RNAi compounds, referred to as rxRNA compounds. It has developed a number of unique forms of rxRNA compounds, all of which have been shown to be potent both in vitro and in preclinical in vivo models. These RNAi compounds include rxRNAori and sd-rxRNA, or 'self-delivering' RNA. The Company is subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and specific waste products. It is also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of bio-hazardous materials.
» More Articles for RXII

Headlines

Articles On GuruFocus.com
comment on RXII Mar 09 2013 
RXi Pharmaceuticals Corp. (RXII) CEO Noah D Beerman buys 10,000 Shares Jul 12 2010 
RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2009 Aug 14 2009 
CytRx Reports 2009 Second Quarter Financial Results Aug 10 2009 

More From Other Websites
7:05 am RXi Pharma granted a patent by the USPTO on its unique delivery system for delivering its... Sep 17 2014
RXi Pharmaceuticals Strengthens Intellectual Property Portfolio Sep 17 2014
RXi Pharmaceuticals Presented an Update on the Company's Dermatology and Ophthalmology Franchises Sep 11 2014
RXi Pharmaceuticals (RXII) Jumps: Stock Moves 11.4% Higher Sep 03 2014
RXi Pharmaceuticals to Present at the Rodman & Renshaw 16th Annual Global Investment Conference Sep 03 2014
RXI PHARMACEUTICALS CORP Financials Aug 22 2014
RXI PHARMACEUTICALS CORP Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 14 2014
RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2014 Aug 14 2014
RXI PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report Aug 14 2014
RXi Pharmaceutical Corporation (NASDAQ: RXII) to Ring The NASDAQ Stock Market Closing Bell Aug 07 2014
RXi Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell Aug 04 2014
RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109... Jul 30 2014
What RXi Pharmaceuticals’ Move to the Russell Microcap Index Means Jul 09 2014
RXi Pharmaceuticals Appoints Peter Campochiaro M.D. to its Scientific Advisory Board Jul 07 2014
RXi Pharmaceuticals Celebrates Expansion of its Operations in Massachusetts Jul 02 2014
RXi Pharmaceuticals Set to Join Russell Microcap Index Jun 25 2014
RXi Pharma Advances sd-rxRNA Platform with Key Patent Jun 09 2014
RXI PHARMACEUTICALS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Submission... Jun 06 2014
Interview With Dr. Geert Cauwenbergh, President And CEO Of RXi Pharmaceuticals Jun 02 2014
RXi Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference May 27 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK